Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Life Sci ; 308: 120971, 2022 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-36130617

RESUMO

Kidney diseases are major health problem and understanding the underlined mechanisms that lead to kidney diseases are critical research points with a marked potential impact on health. Cadmium (Cd) is a heavy metal that occurs naturally and can be found in contaminated food. Kidneys are the most susceptible organ to heavy metal intoxication as it is the main route of waste excretion. The harmful effects of Cd were previously well proved. Cd induces inflammatory responses, oxidative injury, mitochondrial dysfunction and disturbs Ca2+ homeostasis. The nuclear factor-kappa B (NF-κB) is a cellular transcription factor that regulates inflammation and controls the expression of many inflammatory cytokines. Therefore, great therapeutic benefits can be attained from NF-κB inhibition. In this review we focused on certain compounds including cytochalasin D, mangiferin, N-acetylcysteine, pyrrolidine dithiocarbamate, roflumilast, rosmarinic acid, sildenafil, sinapic acid, telmisartan and wogonin and certain plants as Astragalus Polysaccharide, Ginkgo Biloba and Thymus serrulatus that potently inhibit NF-κB and effectively counteracted Cd-associated renal intoxication. In conclusion, the proposed NF-κB involvement in Cd-renal intoxication clarified the underlined inflammation associated with Cd-nephropathy and the beneficial effects of NF-κB inhibitors that make them the potential to substantially optimize treatment protocols for Cd-renal intoxication.


Assuntos
Nefropatias , NF-kappa B , Acetilcisteína/uso terapêutico , Cádmio/toxicidade , Citocalasina D/uso terapêutico , Citocinas/uso terapêutico , Humanos , Inflamação/tratamento farmacológico , Nefropatias/tratamento farmacológico , Nefropatias/metabolismo , NF-kappa B/metabolismo , Polissacarídeos/uso terapêutico , Citrato de Sildenafila/uso terapêutico , Telmisartan/uso terapêutico
2.
Inflammation ; 38(3): 1050-69, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25429758

RESUMO

We hypothesized that if internalization of Staphylococcus aureus could be blocked by using cytochalasin D (an inhibitor of phagocytosis and phagolysosome fusion), then the intracellular entry and survival of the pathogen in host's phagocytic cells recruited to the inflammatory site can be restricted. At the same time, if we use antimicrobial agents (e.g., ciprofloxacin and azithromycin) having potent intracellular and extracellular microbicidal activity against the bacterium that have not entered into the phagosome and remains adhered to the phagocytic cell membrane, then they can be eradicated from the site of infection without compromising the host cell. To validate this, role of ciprofloxacin (CIP) and azithromycin (AZM) in eliminating S. aureus by suppressing the phagocytic activity of macrophages with cytochalasin D before infection was investigated. CIP and AZM were used either alone or in combination with cytochalasin D. Supernatant and lysate obtained from the culture of macrophages were used for quantification of reactive oxygen species, lysozymes, antioxidant enzymes, and cytokines produced. Azithromycin was better than ciprofloxacin in combination with cytochalasin D for eradicating S. aureus and regulating cytokine release. Further studies are required for ensuring proper delivery of this combination at the site of infection.


Assuntos
Azitromicina/uso terapêutico , Ciprofloxacina/uso terapêutico , Citocalasina D/uso terapêutico , Macrófagos/imunologia , Infecções Estafilocócicas/tratamento farmacológico , Animais , Antibacterianos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Antioxidantes/metabolismo , Quimioterapia Combinada , Glutationa/metabolismo , Peróxido de Hidrogênio/metabolismo , Inflamação/tratamento farmacológico , Interferon gama/metabolismo , Interleucina-10/metabolismo , Interleucina-6/metabolismo , Masculino , Camundongos , Testes de Sensibilidade Microbiana , Muramidase/metabolismo , Fagocitose/imunologia , Infecções Estafilocócicas/imunologia , Infecções Estafilocócicas/microbiologia , Staphylococcus aureus/imunologia , Staphylococcus aureus/isolamento & purificação , Staphylococcus aureus/patogenicidade , Superóxido Dismutase/metabolismo , Fator de Necrose Tumoral alfa/metabolismo
3.
Nihon Arukoru Yakubutsu Igakkai Zasshi ; 46(5): 413-23, 2011 Oct.
Artigo em Japonês | MEDLINE | ID: mdl-22256590

RESUMO

Pathophysiological process of ethanol physical dependence and its withdrawal syndrome is supposed to result from adaptive changes in a number of neurotransmission systems, and several reports have demonstrated functional relationship between behavioral responses and neurotransmission systems in ethanol-dependent and -withdrawn animals. However, the molecular mechanisms underlying behavioral responses observed in these animals are still controversial at present. Alterations of beta-adrenergic receptor (beta-AR) function in the brains of mice physically dependent on ethanol were examined because of few available data on functional changes of beta-ARs and its significance in ethanol withdrawal signs. The protein level of beta-ARs also significantly increased in the frontal cortex of mouse with ethanol physical dependence and conditions withdrawn from ethanol after chronic treatment with ethanol vapor for 9 days. Intracerebroventricular administration of nadolol, a non-selective antagonist for beta-ARs, immediately after discontinuation of ethanol inhalation clearly attenuated the expression of withdrawal signs. These findings suggests that ethanol physical dependence induces beta-AR up-regulation, that is their increased number and facilitation of beta-AR signaling, which may at least in part participates in expression of tonic-clonic convulsion as one of ethanol withdrawal signs. We further investigated relationship between actin of cytoskeleton and relapse of alcohol dependence after withdrawal from alcohol vapor inhalation for 9 days. After 3 days of withdrawal from alcohol vapor alcohol-induced place preference was enhanced, which was blocked by the treatment with an actin polymerization inhibitor, cytochalasin D, and anactin depolymerization inhibitor, phalloidin, during 3 days after ethanol withdrawal. These findings suggest that changes in actin turnover on withdrawal from alcohol vapor involve in sensitization of alcohol-induced place preference.


Assuntos
Alcoolismo , Etanol/efeitos adversos , Receptores Adrenérgicos beta/fisiologia , Síndrome de Abstinência a Substâncias , Actinas/metabolismo , Antagonistas Adrenérgicos beta/farmacologia , Antagonistas Adrenérgicos beta/uso terapêutico , Alcoolismo/metabolismo , Alcoolismo/fisiopatologia , Animais , Córtex Cerebral/metabolismo , Citocalasina D/farmacologia , Citocalasina D/uso terapêutico , Epinefrina/fisiologia , Humanos , Camundongos , Faloidina/farmacologia , Faloidina/uso terapêutico , Polimerização/efeitos dos fármacos , Receptores Adrenérgicos beta/metabolismo , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologia , Síndrome de Abstinência a Substâncias/tratamento farmacológico , Transmissão Sináptica , Regulação para Cima
5.
J Periodontol ; 77(5): 826-31, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16671875

RESUMO

BACKGROUND: Several studies have shown that sectioning bundles of collagen fibers in the marginal gingiva during surgical procedures in animals is a distinct stimulus for alveolar bone resorption. Normally, gingival and periodontal fibroblasts, which reside on these collagen fibers, create physiological traction forces generated by the cytoskeleton. By splitting the fibers, traction forces are released, inducing changes in the cytoskeleton and cell shape. In this study, four drugs were selected, including cytochalasin D, EDTA, sodium orthovanadate, and H-7, all influencing the cytoskeleton-integrin-extracellular matrix (ECM) pathway, for their ability to reduce alveolar bone loss by local application. METHODS: The drugs were applied locally only once at the site of mucoperiosteal flap surgery in a rat model. Cytochalasin D (1 microl/microl), EDTA (0.24 mg/microl), sodium orthovanadate (0.02 mg/microl), and H-7 (0.10 microl/microl), each separately, were carried by a protective paste and placed immediately after elevating the flap. The analysis of alveolar bone loss was performed 3 weeks after surgery by scanning the microradiographic films of the mandible cross-sections. The percentages of cross sections with no, moderate, or severe bone loss in treated in comparison to non-treated rats are presented. RESULTS: EDTA, sodium orthovanadate, and H-7 were significantly effective in reducing alveolar bone loss. They were effective in reducing the amount of severe bone loss by 53%, 20%, and 58% while increasing the number of sections with no bone loss by 25%, 23%, and 35%, respectively. Cytochalasin D reduced alveolar bone loss insignificantly. CONCLUSION: EDTA, sodium orthovanadate, and H-7 are effective in reducing alveolar bone loss in rats following mucoperiosteum surgery.


Assuntos
Perda do Osso Alveolar/tratamento farmacológico , Citoesqueleto/efeitos dos fármacos , Doenças Mandibulares/tratamento farmacológico , Doenças Maxilares/tratamento farmacológico , 1-(5-Isoquinolinasulfonil)-2-Metilpiperazina/uso terapêutico , Perda do Osso Alveolar/prevenção & controle , Análise de Variância , Animais , Quelantes/uso terapêutico , Citocalasina D/uso terapêutico , Ácido Edético/uso terapêutico , Inibidores Enzimáticos/uso terapêutico , Masculino , Doenças Mandibulares/prevenção & controle , Doenças Maxilares/prevenção & controle , Inibidores da Síntese de Ácido Nucleico/uso terapêutico , Ratos , Ratos Wistar , Vanadatos/uso terapêutico
6.
Cardiovasc Res ; 69(2): 536-44, 2006 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-16386237

RESUMO

OBJECTIVE: To investigate whether cytochalasin D-eluting stents (CDES) suppress intimal hyperplasia in porcine coronary arteries and to compare the efficacy of paclitaxel and cytochalasin D as inhibitors of vascular smooth muscle cell (SMC) proliferation and platelet aggregation in vitro. METHODS: Rabbit platelet-rich plasma and SMC cultures derived from rabbit aortas were exposed to 10(-8)-10(-5) M cytochalasin D or paclitaxel. Stents directly coated with 2 microg cytochalasin D (low-dose CDES, n=12) and bare stents (n=12) were randomly deployed in the right and left coronary artery of 12 pigs. Six weeks later, neointima was studied using quantitative coronary angiography (QCA) and morphometry. To examine a ten-fold higher dose, polybutyl methacrylate/polyvinyl acetate-coated stents were loaded with 20 microg cytochalasin D. High-dose CDES (n=10) and polymer-only stents (n=11) were deployed in 11 pigs. RESULTS: After 7 days, cytochalasin D (IC(50) 9.9+/-0.4 10(-8) M) and paclitaxel (IC(50) 1.1+/-0.4 10(-8) M) inhibited SMC proliferation in vitro (n=4). In contrast, cytochalasin D (10(-6)-10(-5) M, n=5), but not paclitaxel, attenuated platelet shape change and aggregation induced by ADP. In vivo QCA showed less late lumen loss in low-dose CDES (0.08+/-0.07 vs. 0.32+/-0.08 mm, P=0.05), but morphometry demonstrated only a tendency toward a decreased intimal area. High-dose CDES inhibited both late lumen loss (0.31+/-0.08 vs. 0.91+/-0.06 mm, P<0.01) and intimal area (1.57+/-0.20 vs. 2.46+/-0.22 mm(2), P<0.01). Immunohistochemistry revealed that CDES suppressed peri-strut macrophage recruitment (CD68, P=0.04) and cell proliferation (Ki67, P=0.03) as compared to polymer-only stents without interfering with endothelial cell recovery or the density of alpha-SMC actin staining. Thromboses or edge effects were not observed in either study. CONCLUSIONS: CDES inhibited in-stent hyperplasia. The reduction (39%) with 20 mug CDES was equivalent to that reported for paclitaxel-eluting stents in pigs. Interference with platelet aggregation, SMC migration, SMC proliferation, and leukocyte recruitment could contribute to the benefit. The data indicate that targeting of actin microfilaments has a potential to suppress in-stent restenosis.


Assuntos
Reestenose Coronária/prevenção & controle , Citocalasina D/uso terapêutico , Inibidores da Síntese de Ácido Nucleico/uso terapêutico , Stents , Túnica Íntima/patologia , Animais , Movimento Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Angiografia Coronária , Reestenose Coronária/metabolismo , Citocalasina D/farmacologia , Relação Dose-Resposta a Droga , Hiperplasia , Macrófagos/efeitos dos fármacos , Microscopia Eletrônica , Modelos Animais , Músculo Liso Vascular/citologia , Músculo Liso Vascular/efeitos dos fármacos , Inibidores da Síntese de Ácido Nucleico/farmacologia , Paclitaxel/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Coelhos , Distribuição Aleatória , Suínos , Túnica Íntima/efeitos dos fármacos
7.
Korean J Parasitol ; 38(4): 257-61, 2000 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11138319

RESUMO

This study was focused on the effects of microfilament inhibitor, Cytochalasin D (CD) on the invasiveness of sporozoites of Cryptosporidium spp. into the host cells. MDCK and AGS cell lines were used as host cells for C. parvum and C. muris, respectively. When MDCK cells were pretreated with CD for 1 hr before inoculation of the sporozoites, C. parvum infection was significantly inhibited when compared to the control cells. These inhibitory effects of CD on the rate of infection were dose-dependent. In addition, C. muris infection was hampered when AGS cell lines were pretreated with CD. However, the capability of invasiveness of the sporozoites into the host cells was not greatly influenced by the pretreatment of sporozoites with CD before infection. These results suggest that microfilaments of host cells, rather than parasites, play an important role for the invasion of Cryptosporidium spp.


Assuntos
Citoesqueleto de Actina/efeitos dos fármacos , Criptosporidiose/tratamento farmacológico , Citocalasina D/uso terapêutico , Citoesqueleto de Actina/fisiologia , Animais , Células Cultivadas , Criptosporidiose/etiologia , Cryptosporidium/patogenicidade , Citocalasina D/farmacologia , Cães , Relação Dose-Resposta a Droga , Humanos
8.
J Clin Invest ; 103(3): 347-54, 1999 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-9927495

RESUMO

Increased Ca2+ influx through activated N-methyl-D-aspartate (NMDA) receptors and voltage-dependent Ca2+ channels (VDCC) is a major determinant of cell injury following brain ischemia. The activity of these channels is modulated by dynamic changes in the actin cytoskeleton, which may occur, in part, through the actions of the actin filament-severing protein gelsolin. We show that gelsolin-null neurons have enhanced cell death and rapid, sustained elevation of Ca2+ levels following glucose/oxygen deprivation, as well as augmented cytosolic Ca2+ levels in nerve terminals following depolarization in vitro. Moreover, major increases in infarct size are seen in gelsolin-null mice after reversible middle cerebral artery occlusion, compared with controls. In addition, treatment with cytochalasin D, a fungal toxin that depolymerizes actin filaments, reduced the infarct size of both gelsolin-null and control mice to the same final volume. Hence, enhancement or mimicry of gelsolin activity may be neuroprotective during stroke.


Assuntos
Encéfalo/metabolismo , Transtornos Cerebrovasculares/metabolismo , Gelsolina/metabolismo , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/patologia , Canais de Cálcio/metabolismo , Morte Celular/efeitos dos fármacos , Transtornos Cerebrovasculares/tratamento farmacológico , Transtornos Cerebrovasculares/patologia , Citocalasina D/farmacologia , Citocalasina D/uso terapêutico , Citoesqueleto/metabolismo , Citoesqueleto/patologia , Camundongos , Neurônios/metabolismo , Neurônios/patologia , Inibidores da Síntese de Ácido Nucleico/farmacologia , Inibidores da Síntese de Ácido Nucleico/uso terapêutico , Receptores de N-Metil-D-Aspartato/metabolismo
9.
Pharmacol Res ; 36(2): 141-6, 1997 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-9344643

RESUMO

We investigated the effect of cytochalasin D on anaphylaxis. Cytochalasin D dose-dependently inhibited systemic anaphylaxis induced by compound 48/80 in rats. Especially, cytochalasin D inhibited compound 48/80-induced systemic anaphylaxis 100% with a dose of 1 microg g-1 body weight (BW). Cytochalasin D significantly inhibited serum histamine levels induced by compound 48/80. Cytochalasin D (10(-1) microg g-1 BW) also inhibited local anaphylaxis activated by anti-dinitrophenyl (DNP) IgE to 79.6+/-1.8%. Cytochalasin D dose-dependently inhibited histamine release from the rat peritoneal mast cells activated by compound 48/80 or anti-DNP IgE. The level of cAMP in rat peritoneal mast cells, when cytochalasin D was added, transiently and significantly increased about fourfold compared with that of basal cells. Our studies provide evidence that cytochalasin D will be beneficial in the treatment of anaphylaxis.


Assuntos
Anafilaxia/prevenção & controle , AMP Cíclico/metabolismo , Citocalasina D/uso terapêutico , Liberação de Histamina/efeitos dos fármacos , Mastócitos/efeitos dos fármacos , Inibidores da Síntese de Ácido Nucleico/uso terapêutico , Anafilaxia/induzido quimicamente , Animais , Antiasmáticos/uso terapêutico , Cromolina Sódica/uso terapêutico , Imunoglobulina E , Mastócitos/metabolismo , Anafilaxia Cutânea Passiva/efeitos dos fármacos , Ratos , Ratos Wistar , p-Metoxi-N-metilfenetilamina
10.
Immunol Lett ; 47(1-2): 59-62, 1995.
Artigo em Inglês | MEDLINE | ID: mdl-8537102

RESUMO

A new highly effective pathogenetic therapy for anaphylactic reaction in vivo has been suggested. Forty-three guinea pigs, presensitized with horse serum and divided into two groups, were injected intracardially with 1 ml of 1.6 x 10(-4) M cytochalasin D and 1 ml of 1.6 x 10(-5) M cytochalasin D in DMSO solution at various times before being challenged with the serum. Experimental data not only showed that anaphylactic reaction can be suppressed in vivo by blocking cytoskeletal activity but also demonstrated different pharmacodynamic characteristics of cytochalasin D on clinical course, gravity and outcome of anaphylactic shock in sensitized guinea pigs, depending on the interval between administration of the drug and allergen.


Assuntos
Anafilaxia/prevenção & controle , Citocalasina D/uso terapêutico , Anafilaxia/etiologia , Anafilaxia/imunologia , Animais , Citocalasina D/administração & dosagem , Citoesqueleto/efeitos dos fármacos , Cobaias , Coração , Imunização , Injeções
11.
Calcif Tissue Int ; 53(3): 217-21, 1993 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8242476

RESUMO

The osteoclastic cytoskeleton has been demonstrated to be composed of microfilaments. Osteoclastic multinucleated cells were suspended on dentine slices and cultured for 24 hours in the presence or absence of cytochalasin D (CD), a specific and potent inhibitor of actin filament elongation to determine the role of this cytoskeleton. Cultured cells and co-cultured dentine slices were examined ultrastructurally. Unlike those in control cultures without CD, osteoclasts in CD-treated cultures became spherical in shape and lacked microvilli on their basolateral cell surfaces. Most importantly, CD treatment induced a complete disappearance of the ruffled border-clear zone complexes in osteoclasts, which resulted in loss of osteoclast-cytoplasmic polarity. Morphometric analysis of backscattered electron micrographs of co-cultured dentine slices revealed that CD treatment strongly inhibited the formation of resorption lacunae in a dose-dependent manner. These results suggest that the cytoarchitecture, as well as the bone-resorbing function, of the osteoclast is highly regulated by the F-actin-containing microfilamentous cytoskeleton in the ruffled border-clear zone complex.


Assuntos
Reabsorção Óssea/tratamento farmacológico , Citocalasina D/farmacologia , Osteoclastos/efeitos dos fármacos , Actinas/metabolismo , Animais , Membrana Celular/efeitos dos fármacos , Membrana Celular/ultraestrutura , Células Cultivadas , Citocalasina D/uso terapêutico , Camundongos , Microscopia Eletrônica de Varredura , Microvilosidades/efeitos dos fármacos , Microvilosidades/ultraestrutura , Osteoclastos/metabolismo , Osteoclastos/ultraestrutura
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...